Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Stocking stuffer

Schering-Plough Corp. last week returned European marketing rights for Integrilin eptifibatide to Millennium Pharmaceuticals Inc., while keeping U.S. rights, saying it was reprioritizing its portfolio. That was hardly surprising, given how little Integrilin is

Read the full 340 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE